Exploring structural features of EGFR-HER2 dual inhibitors as anti-cancer agents using G-QSAR approach

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Simultaneous inhibition of Epidermal Growth Factor Receptor (EGFR) and Human Epidermal growth factor Receptor 2 (HER2) is a key strategy in cancer therapy.
• Understanding the structural features of dual-targeting inhibitors is crucial for advancing drug discovery in oncology.

Purpose of the Study:

• To develop and validate quantitative structure-activity relationship (QSAR) models for EGFR and HER2 inhibitors.
• To create a dual-response QSAR model that integrates the activity against both EGFR and HER2.
• To identify specific structural and physicochemical properties that enhance dual inhibitory activity.

Main Methods:

• Development of three G-QSAR models: individual for EGFR, individual for HER2, and a combined dual-model.
• Analysis of structure-activity relationships, including electronegativity, carbon saturation, and atomic properties at specific positions (R1-R4).
• Validation of the dual-model's predictive ability using Williams' plot and applicability domain analysis.

Main Results:

• The dual-model successfully integrated properties influencing both EGFR and HER2 inhibition.
• Key features for enhanced dual activity include specific electronegative character, saturated carbon index at R4, chlorine at R2, and modified shape index at R1/R3.
• Fragment analysis indicated R2 and R4 influence potency, while R1/R3 determine specificity.

Conclusions:

• A single, dual-response QSAR model provides valuable insights into structural determinants of EGFR/HER2 dual inhibition.
• The developed model can guide the design of novel, more effective dual-targeting anti-cancer agents.
• The findings support the use of QSAR in understanding complex drug-receptor interactions for targeted cancer therapies.